TY - JOUR
T1 - Severity of early diagnosed organ/space surgical site infection in elective gastrointestinal and hepatopancreatobiliary surgery
AU - Okui, Jun
AU - Obara, Hideaki
AU - Shimane, Gaku
AU - Sato, Yasunori
AU - Kawakubo, Hirofumi
AU - Kitago, Minoru
AU - Okabayashi, Koji
AU - Kitagawa, Yuko
N1 - Funding Information:
Disclosures outside the scope of this work: Author H.O. received lecture fees from Otsuka Pharmaceutical Factory Inc. Author H.O. was supported by grants from Medtronic Japan Co., Ltd., Japan Blood Products Organization, TAIHO PHARMACEUTICAL CO., LTD, W. L. Gore & Associates, Co., LTD., DAIICHI SANKYO COMPANY, LIMITED, Mitsubishi Tanabe Pharma Corporation, TEIJIN PHARMA LIMITED., KAKEN PHARMACEUTICAL CO., LTD., NOVARTIS PHARMA Co., Ltd., Medtronic Japan Co., Ltd., Japan Blood Products Organization, JMS Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD, MSD KK, KAKEN PHARMACEUTICAL CO., LTD., Mitsubishi Tanabe Pharma Corporation, W. L. Gore & Associates, Co., LTD., NIHON PHARMACEUTICAL CO., LTD., Japan Lifeline Co., Ltd, Medtronic Japan Co., Ltd. JMS Co., Ltd., Japan Blood Products Organization, TAIHO PHARMACEUTICAL CO., LTD. Author Y.K. received lecture fees from CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Factory Inc, ONO PHARMACEUTICAL CO., LTD., SHIONOGI & CO., LTD., Nippon Covidien Inc, AstraZeneca KK, Ethicon Inc, Bristol‐Myers Squibb KK., and Olympus Corporation. Author Y.K. was supported by grants from CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, Yakult Honsha Co. Ltd., ASAHI KASEI PHARMA CORPORATION., Ltd., Otsuka Pharmaceutical Co., Ltd., ONO PHARMACEUTICAL CO., LTD., TSUMURA & CO., KAKEN PHARMACEUTICAL CO. LTD., DAINIPPON SUMITOMO PHARMA Co., Ltd., EA Pharma Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Factory Inc, MEDICON INC., Kyouwa Hakkou Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Astellas Pharma Inc, TEIJIN PHARMA LIMITED., NIHON PHARMACEUTICAL CO., LTD., and Nippon Covidien Inc Author Y.K. held an endowed chair provided by CHUGAI PHARMACEUTICAL CO., LTD. and TAIHO PHARMACEUTICAL CO., LTD, outside the submitted work. Author Y.K. received other compensation from ONO PHARMACEUTICAL CO., LTD., and Bristol‐Myers Squibb KK.
Funding Information:
We sincerely appreciate Mr. Koji Yamamoto, Mr. Shigeyuki Munakata, and all the other members of the hospital information system department at Keio University School of Medicine for their tremendous help in data collection.
Publisher Copyright:
© 2021 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterology.
PY - 2022/5
Y1 - 2022/5
N2 - Background: Organ/space surgical site infection (SSI) is a significant clinical problem. The postdiagnosis course of organ/space SSIs and the impact of its early diagnosis on clinical outcomes are yet to be clarified. Thus, we aimed to investigate the association between the timing of diagnosis and the clinical outcome of organ/space SSI. Methods: This retrospective, single-center cohort study evaluated patients who underwent elective gastrointestinal or hepatopancreatobiliary surgery between 2016 and 2020. Clinical outcomes were compared between the early group (ie, SSI diagnosed until postoperative day [POD] 4) and normal-late group (ie, SSI diagnosed after POD 5). The primary outcome was the final C-reactive protein (CRP) level within 14 d after organ/space SSI diagnosis. Results: In total, 110 patients were evaluated. The median time of diagnosis was 7 d postoperatively (interquartile range, 5–9 d postoperatively). Compared with the normal-late group, the early group included a higher proportion of patients with Clavien–Dindo grade ≥IIIb (8/21 vs 11/89, P =.01), higher final CRP value within 14 d after SSI diagnosis (mean, 4.49 mg/dL vs 2.27 mg/dL, P =.01), longer postoperative length of hospitalization (median, 45.0 d vs 33.0 d; P =.028), and worse 1-y overall survival rate (74.8% vs 89.3%, P =.08). Conclusion: Early diagnosed organ/space SSI are originally severe and may therefore be detected earlier. Importantly, early diagnosed organ/space SSI is likely to be severe and refractory.
AB - Background: Organ/space surgical site infection (SSI) is a significant clinical problem. The postdiagnosis course of organ/space SSIs and the impact of its early diagnosis on clinical outcomes are yet to be clarified. Thus, we aimed to investigate the association between the timing of diagnosis and the clinical outcome of organ/space SSI. Methods: This retrospective, single-center cohort study evaluated patients who underwent elective gastrointestinal or hepatopancreatobiliary surgery between 2016 and 2020. Clinical outcomes were compared between the early group (ie, SSI diagnosed until postoperative day [POD] 4) and normal-late group (ie, SSI diagnosed after POD 5). The primary outcome was the final C-reactive protein (CRP) level within 14 d after organ/space SSI diagnosis. Results: In total, 110 patients were evaluated. The median time of diagnosis was 7 d postoperatively (interquartile range, 5–9 d postoperatively). Compared with the normal-late group, the early group included a higher proportion of patients with Clavien–Dindo grade ≥IIIb (8/21 vs 11/89, P =.01), higher final CRP value within 14 d after SSI diagnosis (mean, 4.49 mg/dL vs 2.27 mg/dL, P =.01), longer postoperative length of hospitalization (median, 45.0 d vs 33.0 d; P =.028), and worse 1-y overall survival rate (74.8% vs 89.3%, P =.08). Conclusion: Early diagnosed organ/space SSI are originally severe and may therefore be detected earlier. Importantly, early diagnosed organ/space SSI is likely to be severe and refractory.
KW - abdominal abscess
KW - anastomotic leak
KW - digestive system surgical procedures
KW - pancreatic fistula
KW - surgical wound infection
UR - http://www.scopus.com/inward/record.url?scp=85121502886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121502886&partnerID=8YFLogxK
U2 - 10.1002/ags3.12539
DO - 10.1002/ags3.12539
M3 - Article
AN - SCOPUS:85121502886
SN - 2475-0328
VL - 6
SP - 445
EP - 453
JO - Annals of Gastroenterological Surgery
JF - Annals of Gastroenterological Surgery
IS - 3
ER -